Trevor Allred
Stock Analyst at Oppenheimer
(4.73)
# 148
Out of 5,241 analysts
19
Total ratings
83.33%
Success rate
49.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Downgrades: Perform | n/a | $16.22 | - | 2 | Mar 5, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $275 → $277 | $213.21 | +29.92% | 9 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $83 → $81 | $66.13 | +22.49% | 2 | Feb 25, 2026 | |
| LEGN Legend Biotech | Initiates: Outperform | $75 | $27.55 | +172.23% | 1 | Jan 7, 2026 | |
| DSGN Design Therapeutics | Initiates: Outperform | $18 | $14.37 | +25.26% | 1 | Jan 7, 2026 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $80 | $32.45 | +146.53% | 2 | Sep 23, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $85 | $114.24 | -25.60% | 1 | Sep 9, 2025 | |
| INVA Innoviva | Initiates: Outperform | $35 | $21.97 | +59.31% | 1 | Aug 11, 2025 |
Theravance Biopharma
Mar 5, 2026
Downgrades: Perform
Price Target: n/a
Current: $16.22
Upside: -
Ligand Pharmaceuticals
Feb 27, 2026
Maintains: Outperform
Price Target: $275 → $277
Current: $213.21
Upside: +29.92%
BridgeBio Pharma
Feb 25, 2026
Maintains: Outperform
Price Target: $83 → $81
Current: $66.13
Upside: +22.49%
Legend Biotech
Jan 7, 2026
Initiates: Outperform
Price Target: $75
Current: $27.55
Upside: +172.23%
Design Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $18
Current: $14.37
Upside: +25.26%
MBX Biosciences
Sep 23, 2025
Maintains: Outperform
Price Target: $38 → $80
Current: $32.45
Upside: +146.53%
Palvella Therapeutics
Sep 9, 2025
Initiates: Outperform
Price Target: $85
Current: $114.24
Upside: -25.60%
Innoviva
Aug 11, 2025
Initiates: Outperform
Price Target: $35
Current: $21.97
Upside: +59.31%